John Muir Health logo
  • Patients
    About MyChart
    Locating Patients
    Medicare
    New Patients
    Payment & Insurance
    Physician Open Payments Notice
    Preparing for Surgery
    Pre-Register for a Visit
    Registration & Forms
    Request a Health Record
    Security Center
    Video Visits
    Why Choose Us
  • Services
    Addiction Medicine
    Behavioral Health
    Cancer
    Cardiovascular Services
    Digestive Health
    Emergency Services
    Lab Services
    Medical Imaging
    Neurosciences
    Orthopedics
    Pediatrics
    Physical Rehabilitation
    Pregnancy & New Parent
    Primary Care
    Urgent Care
    ALL SERVICES
  • Education
    Classes, Screenings & Support Groups
    Clinical Trials
    Conditions & Treatments
    Health & Wellness
  • Health Professionals
    Careers
    Clinical Research
    Family Medicine Residency Program
    John Muir Medical Group
    Medical Staff
    Nursing
    Pharmacy Residency Program
    Resources
    Training & Education
    Video & Publication Center
  • About Us
    Annual Reports
    Awards & Recognition
    Board of Directors
    Community Commitment
    Employers, Brokers, & Health Plans
    Executive Team
    Make a Gift
    Mission & Vision
    Partnerships
    Media Center
MyChart Login
  • Find a location
  • Find a doctor
  • Pay a bill
  • Find a job
✕

Latest information on COVID-19 >

Urologic Cancer Systemic Treatments

  1. Home
  2. Services
  3. Cancer
  4. What We Treat
  5. Urologic Cancer Services
  6. Treatments
  7. Systemic Treatments
Treatments
  • Surgery
  • Systemic Treatments

Systemic Treatment Options

John Muir Health is on the forefront of using innovative systemic treatments (chemotherapy, biologic therapy or hormonal treatment) to treat urological cancer.

Some creative forms of non-surgical therapy options may help to prevent or control the growth of your cancer.

Chemotherapy

Chemotherapy is sometimes used to treat advance cases of prostate cancer and is rarely used to treat kidney cancer, usually only for recurrent kidney cancer, cancer that has metastasized to other organs, or for transitional-cell carcinoma, which is a less common form of kidney cancer. 

Patients with superficial bladder cancer may receive a non-systemic form of chemotherapy known as intravesical chemotherapy in conjunction with surgery to control the cancer.

Systemic chemotherapy is sometimes used alone or in combination with radiation oncology to eradicate the last remnants of the bladder cancer. Patients with a metastatic bladder cancer that is spreading to other organs and is, therefore, not conducive to surgical removal may undergo chemotherapy, using a combination of anticancer drugs.

Patients with advanced stage or metastatic testicular cancer also will often receive chemotherapy in combination with surgery for treatment.

Through its active research program with regional and national affiliations, John Muir Health can provide patients with access to investigational chemotherapy drugs if you and your doctor decide that’s the best course of action.

Biologic Therapy

John Muir Health offers leading edge minimally invasive biotherapy options to treat bladder and kidney cancer.

For the treatment of superficial bladder cancer, we inject a bacterial agent known as Bacille Calmette-Guérin (BCG) into the bladder via the urethra that causes a tumor-fighting inflammatory response within the bladder. The patient is generally treated once a week for six weeks, then put on a maintenance regimen to prevent recurrence. This treatment does produce some side effects that are very tolerable for most.

Patients with advanced kidney cancer that has metastasized (spread) may receive immunotherapy to stimulate the body’s own immune system in addition to surgery to stop the cancer from growing.  Another type of biologic agent puts the cancer in a holding pattern by blocking the hormones that stimulate its growth.

Hormonal Treatment ­

For the treatment of prostate cancer, hormonal therapy is sometimes used before radiation to shrink the tumor or to treat patients with metastatic cancer who experience a relapse. Hormone-blocking drugs stop the production of testosterone, which can stimulate the growth of prostate cancer cells.

Learn how we support you through recovery

Hi! I'm here to help answer your questions.
Chat
ABOUT
About Us
Board of Directors
Executive Team
Awards & Recognition
Partnerships
Community Commitment
Employers, Brokers & Health Plans
NEWS & PRESS
Media Center
Annual Reports
GET INVOLVED
Careers
Volunteer
Make a Gift
CONTACT
Email Us
PRIVACY
Patient Privacy
Website Privacy
Terms of Use
Security Center
Follow Us

© John Muir Health All rights reserved.

John Muir Health is accredited by The Joint Commission. 

We use cookies to measure website traffic and personalize content for a better browsing experience. By using this website, you consent to our cookies. For more details, see our Website Privacy Policy.